IDEAYA Biosciences Inc Stock News

SOUTH SAN FRANCISCO, Calif. , Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that an abstract with data from the company's single-arm, Phase 1/2 trial of darovasertib in combination with crizotinib in first-line metastatic uveal melanoma (mUM) was accepted for an oral presentation at the 2025 Society for Mela...

SOUTH SAN FRANCISCO, Calif. , Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 28, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 139,800 shares of the Com...

SOUTH SAN FRANCISCO, Calif. , Aug. 25, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.

SOUTH SAN FRANCISCO, Calif. , Aug. 18, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its in-person R&D Day in conjunction with the company's 10-Year Anniversary on September 8, 2025 in New York from 8:00-10:30am EST.

IDEAYA Biosciences (IDYA -3.52%), a precision oncology company focused on developing targeted therapies for cancer, reported its second-quarter earnings on August 5, 2025. The company did not report any revenue for the quarter.

IDEAYA Biosciences' recent pipeline updates highlight promising clinical trial results, strengthening my confidence in their long-term growth potential. A robust financial position supports ongoing R&D investments and mitigates near-term cash flow risks. Key strengths include a diversified product portfolio and strong management execution, though regulatory and competitive risks remain.

Phase 2/3 trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative metastatic uveal melanoma (MUM) on track to report median PFS data by year-end 2025; potential to enable a U.S. accelerated approval filing First-reported median overall survival data in over 40 1L MUM patients from single-arm Phase 2 trial of the darovasertib and crizotinib combination to be provided at a medi...

SOUTH SAN FRANCISCO, Calif. , Aug. 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 31, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 31,400 shares of the Company...